<DOC>
	<DOCNO>NCT02854319</DOCNO>
	<brief_summary>The objective REPRISE EDGE study confirm acute performance safety LOTUS Edge™ Valve System use Lotus™ iSleeve™ Introducer Set transcatheter aortic valve implantation ( TAVI ) symptomatic patient severe calcific aortic stenosis consider high risk surgical valve replacement .</brief_summary>
	<brief_title>REpositionable Percutaneous Replacement NatIve StEnotic Aortic Valve Through Implantation LOTUS EDGE Valve System</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject ≥70 year age . 2 . Subject document calcific native aortic valve stenosis initial aortic valve area ( AVA ) &lt; 1.0 cm2 ( AVA index &lt; 0.6 cm2/m2 ) either mean pressure gradient &gt; 40 mm Hg jet velocity &gt; 4 m/s , measure echocardiography and/or invasive hemodynamics . Note : In case low flow , low gradient aortic stenosis dobutamine use assess grade aortic stenosis ( maximum dobutamine dose 20 mcg/kg/min recommend ) c ; subject may enrol echocardiographic criterion meet augmentation . 3 . Subject document aortic annulus size ≥20 mm ≤27 mm base preprocedure diagnostic imaging . 4 . Subject symptomatic aortic valve stenosis NYHA Functional Class ≥ II . 5 . Subject consider high risk surgical valve replacement base least one following : STS score ≥8 % , and/or Agreement heart team ( must include inperson evaluation experience cardiac surgeon ) subject high operative risk serious morbidity mortality surgical valve replacement . 6 . Heart team ( must include experienced cardiac surgeon ) assessment subject likely benefit valve replacement 7 . Subject ( legal representative ) understand study requirement treatment procedure , provide write informed consent . 8 . Subject , family member and/or legal representative agree ( ) subject capable return study hospital require schedule follow visit . 1 . Subject congenital unicuspid bicuspid aortic valve . 2 . Subject acute myocardial infarction within 30 day index procedure ( define Qwave MI nonQwave MI total CK elevation ≥ twice normal presence CKMB elevation and/or troponin level elevation ) . 3 . Subject cerebrovascular accident transient ischemic attack within past 6 month , permanent neurologic defect prior study enrollment . 4 . Subject dialysis serum creatinine level &gt; 3.0 mg/dL 265 µml/L . 5 . Subject preexist prosthetic aortic mitral valve . 6 . Subject &gt; 3+ mitral regurgitation , &gt; 3+ aortic regurgitation &gt; 3+ tricuspid regurgitation . 7 . Subject need emergency surgery reason . 8 . Subject history endocarditis within 12 month index procedure evidence active systemic infection sepsis . 9 . Subject echocardiographic evidence new intracardiac vegetation intraventricular paravalvular thrombus require intervention . 10 . Subject Hgb &lt; 9 g/dL , platelet count &lt; 50,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell count &lt; 1,000 cells/mm3 . 11 . Subject require chronic anticoagulation therapy implant procedure treat warfarin ( anticoagulant permit first month ) least 1 month concomitant either aspirin clopidogrel . Note : An alternative P2Y12 inhibitor may prescribe subject allergic intolerant clopidogrel 12 . Subject gastrointestinal bleed require hospitalization transfusion within past 3 month , clinically significant bleed diathesis coagulopathy would preclude treatment require antiplatelet regimen , refuse transfusion . 13 . Subject know hypersensitivity contrast agent adequately premedicated , know hypersensitivity aspirin , thienopyridines , heparin , nickel , titanium , polyurethane . 14 . Subject life expectancy le 12 month due noncardiac , comorbid condition base assessment investigator time enrollment . 15 . Subject hypertrophic obstructive cardiomyopathy . 16 . Subject therapeutic invasive cardiac procedure within 30 day prior index procedure ( except balloon aortic valvuloplasty pacemaker implantation allow ) . 17 . Subject untreated coronary artery disease , opinion treat physician , clinically significant require revascularization . 18 . Subject document left ventricular ejection fraction &lt; 30 % . 19 . Subject cardiogenic shock hemodynamic instability require inotropic support mechanical support device . 20 . Subject severe vascular disease would preclude safe access ( e.g. , aneurysm thrombus cross safely , mark tortuosity , significant narrowing abdominal aorta , severe unfold thoracic aorta , symptomatic carotid vertebral disease ) . 21 . Subject arterial access acceptable LOTUS Edge delivery system compatible Lotus iSleeve Introducers define Directions For Use , severe iliofemoral tortuosity calcification would prevent safe placement either introducer sheath . 22 . Current problem substance abuse ( e.g. , alcohol , etc. ) . 23 . Subject participate another investigational drug device study reach primary endpoint . 24 . Subject permanent pacemaker class I II indication pacemaker implantation ( base late available ESC guideline ) .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>